New and Evolving Therapeutic Targets in Lung Cancer: Expert Guidance in Incorporating Biomarker Testing to Deliver Precision Therapy

Gain expert insights on how to test for new and emerging molecular targets and incorporate targeted agents into the care of your patients with lung cancer with downloadable slides and on-demand Webcasts from live meetings, biomarker summary handouts, and a decision support tool providing the latest individualized guidance on precision therapy for NSCLC.
Todd M. Bauer, MD
Lyudmila Bazhenova, MD
Leora Horn, MD, MSc, FRCPC
Edward S. Kim, MD, FACP
Eric Q. Konnick, MD, MS
Nathan Pennell, MD, PhD
person default
Vamsidhar Velcheti, MD

Downloadable Slidesets

Download this short summary slideset of key takeaway points from a live CCO meeting series on the evolving use of biomarkers for precision therapy in lung cancer.

Eric Q. Konnick, MD, MS Nathan Pennell, MD, PhD Released: May 29, 2020

Download this short summary slideset of key takeaways from a live CCO Webinar focused on the use of new biomarkers critical to lung cancer care today.

Leora Horn, MD, MSc, FRCPC Edward S. Kim, MD, FACP Released: June 26, 2020

Download these slides from our live meeting series to gain expert insights on how to integrate new and emerging molecular targets into the care of your patients with lung cancer.

Eric Q. Konnick, MD, MS Nathan Pennell, MD, PhD Released: May 5, 2020

Download this slideset on new and emerging molecular targets critical to lung cancer care, including expert insight on NTRK fusions, RET fusions, and MET exon 14 skipping mutations.

Leora Horn, MD, MSc, FRCPC Edward S. Kim, MD, FACP Released: June 25, 2020

Download this slideset for expert insights on the role of biomarkers in the optimal use of immunotherapy in the care of patients with NSCLC.

Leora Horn, MD, MSc, FRCPC Edward S. Kim, MD, FACP Released: June 25, 2020

ClinicalThought

Which emerging biomarkers have the most potential to affect personalized care of our patients with NSCLC? Read my thoughts on testing for and targeting RET, MET exon 14, and more.

Todd M. Bauer, MD Released: February 28, 2020

As targeted therapy prolongs survival in our patients with oncogene-driven NSCLC, CNS metastases and leptomeningeal carcinomatosis are more likely to develop as part of the disease course. Read my thoughts on what factors I consider when treating these challenging disease manifestations.

Lyudmila Bazhenova, MD Released: April 28, 2020

Vamsidhar Velcheti, MD, provides his thoughts on the clinical implications of the recent approval of selpercatinib for RET fusion–positive NSCLC in this commentary.

person default Vamsidhar Velcheti, MD Released: June 25, 2020

Downloadable Resource

Download this PDF resource for clinical insights on new and established clinical biomarkers guiding NSCLC management, including best testing practices.

Released: June 19, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?